A case of large-cell neuroendocrine carcinoma harboring an EML4-ALK rearrangement with resistance to the ALK inhibitor crizotinib

Journal of Thoracic Oncology

Volumn 9, Issue 6, 2014, Pages

  Omachi, Naoki ^a   Shimizu, Shigeki ^b   Kawaguchi, Tomoya ^a   Tezuka, Kenji ^b   Kanazu, Masaki ^a   Tamiya, Akihiro ^a   Asami, Kazuhiro ^a   Okishio, Kyoichi ^a   Kitaichi, Masanori ^b   Atagi, Shinji ^a  

^a Department of Internal Medicine ^*  (Japan)

^b NATIONAL HOSPITAL ORGANIZATION KINKI CHUO CHEST MEDICAL CENTER   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CRIZOTINIB; EML4-ALK FUSION PROTEIN, HUMAN; IMMUNOGLOBULIN G; K 18; MELPHALAN; ONCOPROTEIN; PYRAZOLE DERIVATIVE; PYRIDINE DERIVATIVE;

ADULT; ARTICLE; BREAST METASTASIS; CANCER RESISTANCE; CASE REPORT; EML4 ALK FUSION GENE; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; FUSION GENE; GENE AMPLIFICATION; GENE REARRANGEMENT; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LARGE CELL NEUROENDOCRINE CARCINOMA; LUNG ADENOCARCINOMA; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRANSBRONCHIAL BIOPSY; BREAST NEOPLASMS; CARCINOMA, LARGE CELL; CARCINOMA, NEUROENDOCRINE; DRUG RESISTANCE; GENETICS; LUNG NEOPLASMS; PATHOLOGY; SECONDARY; SKIN NEOPLASMS;

ADULT; BREAST NEOPLASMS; CARCINOMA, LARGE CELL; CARCINOMA, NEUROENDOCRINE; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE REARRANGEMENT; HUMANS; IMMUNOGLOBULIN G; LUNG NEOPLASMS; MELPHALAN; ONCOGENE PROTEINS, FUSION; PYRAZOLES; PYRIDINES; SKIN NEOPLASMS;

EID: 84901438090     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0000000000000103     Document Type: Article

References (7)

1. Soda M, Choi YL, Enomoto M, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 2007;448:561-566. (Pubitemid 47206930)
2. Wong DW, Leung EL, So KK, et al.; University of Hong Kong Lung Cancer Study Group. The EML4-ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild-type EGFR and KRAS. Cancer 2009;115:1723-1733.
3. Takeuchi K, Soda M, Ishikawa Y, et al. RET, ROS1 and ALK fusions in lung cancer. Nat Med 2012;18:378-381.
4. Toyokawa G, Takenoyama M, Taguchi K, et al. An extremely rare case of small-cell lung cancer harboring variant 2 of the EML4-ALK fusion gene. Lung Cancer 2013;81:487-490.
5. Toyokawa G, Taguchi K, Ohba T, et al. First case of combined small-cell lung cancer with adenocarcinoma harboring EML4-ALK fusion and an exon 19 EGFR mutation in each histological component. J Thorac Oncol 2012;7:e39-e41.
6. Nakamura H, Tsuta K, Yoshida A, et al. Aberrant anaplastic lymphoma kinase expression in high-grade pulmonary neuroendocrine carcinoma. J Clin Pathol 2013;66:705-707.
7. Kwak EL, Bang YJ, Camidge DR, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 2010;363:1693-1703.